Literature DB >> 20460143

Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice.

Simon Brooks1, Gemma Higgs, Nari Janghra, Lesley Jones, Stephen B Dunnett.   

Abstract

To determine the suitability of mouse models of disease for therapeutic trials, the models must be characterised to determine their similarity to the human condition, and utility for specific therapeutic approaches. The YAC128 mouse model of HD has been bred on to C57BL/6J background in order to provide a mouse model of the disease better suited to behavioural testing, than the visually impaired original line on the FVB background. In the present study, the C57BL/6J YAC128 mice were assessed on several behavioural tasks bi-monthly between 4 and 24 months of age. On the rotarod early and stable deficits were demonstrated in the YAC128 mice from 4 months of age indicating an early abnormality in motor coordination. Early and stable deficits were also found on the balance beam measures of latency to orientate towards the beam and time to traverse it. Measures of fore and hind limb footslips on the balance beam demonstrated early and progressive limb use deficits in the YAC128 mice. On a 3-stage Morris water maze protocol, the YAC128 mice took longer and travelled further to find the hidden platform in each of the 3 locations, indicative of a spatial learning deficit. The YAC128 mice were also less reactive to the primary startle stimuli and the effects of the prepulse which may suggest striatal dysfunction. As a measure of general well being, the body weights of the mice were recorded and demonstrated increased weight in the YAC128 mice until 14 months of age, when they became comparable to that of their wildtype littermates. The YAC128 mouse on the C57BL/6J background has an early, robust and severe behavioural phenotype that shares some similarity to human HD symptomatology.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20460143     DOI: 10.1016/j.brainresbull.2010.05.005

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  13 in total

1.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

2.  A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.

Authors:  Andrew H Coles; Maire F Osborn; Julia F Alterman; Anton A Turanov; Bruno M D C Godinho; Lori Kennington; Kathryn Chase; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2015-11-23       Impact factor: 5.486

3.  Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.

Authors:  Tristano Pancani; Daniel J Foster; Mark S Moehle; Terry Jo Bichell; Emma Bradley; Thomas M Bridges; Rebecca Klar; Mike Poslusney; Jerri M Rook; J Scott Daniels; Colleen M Niswender; Carrie K Jones; Michael R Wood; Aaron B Bowman; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

Review 4.  Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Authors:  Pawel M Switonski; Wojciech J Szlachcic; Agnieszka Gabka; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

5.  In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model.

Authors:  Jessica J Steventon; David J Harrison; Rebecca C Trueman; Anne E Rosser; Derek K Jones; Simon P Brooks
Journal:  J Huntingtons Dis       Date:  2015

6.  Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability.

Authors:  Randi-Michelle Cowin; Nghiem Bui; Deanna Graham; Jennie R Green; Stephan Grueninger; Lisa A Yuva-Paylor; Arsalan U Syed; Andreas Weiss; Richard Paylor
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

7.  Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington's disease are not reflected in mutant Huntingtin inclusion prevalence.

Authors:  Zubeyde Bayram-Weston; Timothy C Stone; Peter Giles; Linda Elliston; Nari Janghra; Gemma V Higgs; Peter A Holmans; Stephen B Dunnett; Simon P Brooks; Lesley Jones
Journal:  BMC Genomics       Date:  2015-12-21       Impact factor: 3.969

8.  A Longitudinal Operant Assessment of Cognitive and Behavioural Changes in the HdhQ111 Mouse Model of Huntington's Disease.

Authors:  Emma Yhnell; Stephen B Dunnett; Simon P Brooks
Journal:  PLoS One       Date:  2016-10-04       Impact factor: 3.240

Review 9.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

10.  Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.

Authors:  Ivan Rattray; Edward J Smith; William R Crum; Thomas A Walker; Richard Gale; Gillian P Bates; Michel Modo
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.